OBJECTIVE: Renin-angiotensin system (RAS) regulates adipogenic response with adipocyte hypertrophy by increasing oxidative stress. Recent studies have shown the role of peroxisome proliferator-activated receptor-d (PPARd) agonist in attenuation of angiotensin II-induced oxidative stress. The aim of this study was to explore a potential mechanistic link between PPARd and the cytoprotective enzyme heme oxygenase-1 (HO-1) and to elucidate the contribution of HO-1 to the adipocyte regulatory effects of PPARd agonism in an animal model of enhanced RAS, the Goldblatt 2 kidney 1 clip (2K1C) model. METHOD: We first established a direct stimulatory effect of the PPARd agonist (GW 501516) on the HO-1 gene by demonstrating increased luciferase activity in COS-7 cells transfected with a luciferase-HO-1 promoter construct. Sprague-Dawley rats were divided into four groups: sham-operated animals, 2K1C rats and 2K1C rats treated with GW 501516, in the absence or presence of the HO activity inhibitor, stannous mesoporphyrin (SnMP). RESULTS: 2K1C animals had increased visceral adiposity, adipocyte hypertrophy, increased inflammatory cytokines, increased circulatory and adipose tisssue levels of renin and Ang II along with increased adipose tissue gp91 phox expression (Po0.05) when compared with sham-operated animals. Treatment with GW 501516 increased adipose tissue HO-1 and adiponectin levels (Po0.01) along with enhancement of Wnt10b and b-catenin expression. HO-1 induction was accompanied by the decreased expression of Wnt5b, mesoderm specific transcript (mest) and C/EBPa levels and an increased number of small adipocytes (Po0.05). These effects of GW501516 were reversed in 2K1C animals exposed to SnMP (Po0.05). CONCLUSION: Taken together, our study demonstrates, for the first time, that increased levels of Ang II contribute towards adipose tissue dysregulation, which is abated by PPARd-mediated upregulation of the heme-HO system. These findings highlight the pivotal role and symbiotic relationship of HO-1, adiponectin and PPARd in the regulation of metabolic homeostasis in adipose tissues.
INTRODUCTION
Adipose tissues are a site for energy storage and also functions as an endocrine organ that secretes various biologically active molecules called adipocytokines. Hyperplasia and hypertrophy of adipocytes is central to pathological conditions such as obesity and metabolic syndrome, [1] [2] [3] conditions that are frequently associated with chronic redox imbalances. Reactive oxygen species (ROS) regulate the adipogenic process where ROS-induced adipocyte hypertrophy has been observed. [4] [5] [6] In this regard, angiotensin II activates cellular oxidases and precipitates redox imbalance. 7 Angiotensin II has also been reported to regulate adipocyte growth and differentiation along with modulation of adipocytokine expression and release. 8 Increased Ang II levels in adipocytes induce oxidative stress and attenuate adiponectin release. 4 The Goldblatt 2 kidney 1 clip (2K1C) model is a model for reno-vascular hypertension characterized by activation of the renin-angiotensin system (RAS) 9 whose local adipose tissue effects have recently been reported. 10 However, precise regulatory effect of Ang II on adipose tissue is still unclear and needs further examination.
Peroxisome proliferator-activated receptor-d (PPARd), a member of the PPAR nuclear receptor family, is a ligand-activated transcriptional factor with a multifunctional role in lipid metabolism, namely, to increase lipolysis, promote fatty acid catabolism and energy expenditure in adipose tissues. 11, 12 PPARd forms obligate heterodimers with the retinoid X receptor and bind to defined PPAR elements in the promoter region of target genes. PPARd is expressed in many tissues, including metabolically active sites such as the liver, muscle and fat, and its role in the metabolic syndrome is currently elucidated. 12 PPARd is activated by oxidative stress and has an important role in decreasing inflammation, apoptosis and leukocyte adhesion. Recent studies have shown the role of PPARd agonist in the attenuation of angiotensin II-induced oxidative stress in vascular smooth muscles. 13 Additionally, upregulation of the antioxidant enzyme system, that is, the heme-heme oxygenase system (HO) has also been shown to reduce Ang II-induced oxidative stress, with abatement of associated cardiovascular complications. HO system comprises of two isoforms, a constitutively expressed isoform called HO-2 and an inducible HO-1.
14 HO-1 is stimulated by a variety of stimuli, including heavy metals, ROS, NO, Ang II and cytokines. [15] [16] [17] Induction of the HO-1 gene, both in vivo and in cell cultures, reduces adipocyte hypertrophy with an increase in adiponectin levels and the number of small adipocytes, which are regarded as 'healthy' insulin-sensitive adipocytes. 18, 19 This study examines adipose tissue effects of increased Ang II, both in vitro and in vivo (Goldblatt's 2K1C model). In addition, we use this model to evaluate a possible interplay between PPARd and HO-1 in regulating adipocyte morphology and function, as both HO-1 and PPARd have been shown to attenuate Ang IIinduced redox imbalance and associated pathologies. In contextual light, the present study aims to explore the effectiveness of a PPARd agonist in the prevention of Ang II-induced adipocyte dysfunction and the possible interaction between PPARd and HO-1 system in a model of enhanced oxidative stress. This novel study corroborates the existence of a PPARd-HO-1 axis whose direct stimulation via the administration of an exogenous PPARd agonist induces HO-1 expression, abates RAS-associated adipocyte dysfunction and induces adipocyte remodeling with smaller adipocytes while decreasing inflammation and increasing adiponectin secretion.
MATERIALS AND METHODS

Animal treatment
All animal studies were approved by the New York Medical College Animal Care and Use Committee in accordance with the National Institutes of Health Guidelines for Care and Use of Laboratory Animals. Forty, 8-week-old Sprague-Dawley rats were used in the studies. Sprague-Dawley rats were divided into four groups: sham-operated animals, 2K1C rats and 2K1C rats treated with GW 501516, in the absence or presence of the HO activity inhibitor, stannous mesoporphyrin (SnMP). All surgically altered rats were fitted with a 0.25-mm U-shaped silver clip with an internal gap of 0.25 mm around the left renal artery. GW501516 (Enzo Life Sciences Inc., Plymouth Meeting, PA, USA) was dissolved in dimethyl sulfoxide and suspended in 0.5% carboxymethylcellulose. Immediately after surgery, GW 501516 was administered via oral gavage daily for 3 weeks at a concentration of 3 mg kg À 1 body weight. SnMP was injected intraperitoneally, three times a week at a dose of 20 mg kg À 1 of body weight, for 2 weeks. Blood pressure was measured by the tail cuff method immediately before surgery and then 3 weeks after surgery. Before the experiment, rats were all acclimatised to the tail cuff method. Rats were placed in a heat-controlled box (36-38 1C) for approximately 10 min before applying the tail cuff. The mean of a minimum of five measurements was obtained from each rat. After a 6-h fast, rats were anesthetized with sodium pentobarbital (65 mg kg À 1 , intraperitoneally) and blood was obtained from a tail vein for glucose measurement using a glucometer (Lifescan Inc., Miligitas, CA, USA). At the time of killing, body weight, liver weight and visceral fat content of all rats was measured. Blood samples were collected in K 3 EDTA tubes at killing and the plasma was separated. Samples were flash frozen in liquid nitrogen and maintained at À 80 1C until assayed.
Gene reporter assay
Cos7 cells were grown to 90% confluence in 24-well plates and then transiently transfected with expression vectors for PPARd and RXR using Lipofectamine 2000, according to the manufacturer's protocol. A luciferase plasmid construct containing 15 kb of the HO-1 promoter (HO-1-15 kb-Luc reporter; courtesy of Dr Jawed Alam) was co-transfected, as appropriate, along with a pRL-CMV renilla reporter to normalize for transfection efficiency. Twenty-four hours post transfection, cells were treated with either vehicle or GW501516 (PPARd agonist) for an additional 24 h until harvest. Cell lysates were prepared by repeated freezing and thawing in Promega lysis buffer (Promega, Madison, WI, USA), and luciferase activity was measured using Promega's luciferase assay system in a Dual luciferase plate reader (Promega).
Cell culture and differentiation into adipocytes
Frozen mouse preadipocytes (3T3L-1) were purchased from ATTC (ATTC, Manassas, VA, USA). After thawing, 3T3L cells were resuspended in a Dulbecco's Modified Eagle Medium (DMEM; Invitrogen, Carlsbad, CA, USA) supplemented with 10% heat inactivated fetal bovine serum (FBS; Invitrogen) and 1% antibiotic/antimycotic solution (Invitrogen). The cells were plated at a density of 1-5 Â 10 6 cells per 100 cm 2 dish. The cultures were maintained at 37 1C in a 5% CO 2 incubator and the medium was changed after 48 h and every 3B4 days thereafter. When the 3T3L cells were confluent, the cells were recovered by the addition of 0.25% trypsin/EDTA (Invitrogen). 3T3L cells (Passages 2 and 3) were plated in a 75-cm 2 flask at a density of 1-2 Â 10 4 cells and cultured in DMEM with 10% FBS until 80% confluence was achieved. The medium was replaced with adipogenic medium, and the cells were cultured for an additional 7 days as described previously. 5 Cells were treated every alternate day with GW501516 (10 mM), Ang II (10 mM) and SnMP (5 mM) for 7 days in mouse preadipocytes.
Effect of Ang II on adipogenesis
To measure the effect of increasing Ang II concentration on MSC-derived adipocyte differentiation, cells were treated with 0. Determination of adipocyte size and number Visceral adipose tissue was collected from all the groups and prepared for morphological analysis, as previously described. 20 Samples were fixed in 4% paraformaldehyde for 24 h, cut into small pieces and embedded in paraffin for histological analysis. The samples were cut by microtome (5 mM thick), mounted on D-polylisinated glass slides, deparaffinized in xylene and stained with haematoxylin and eosin for the evaluation of adipocyte size. Each sample was examined and evaluated for the adipocyte size and number using an optical microscopy ( Â 200 magnification). Specifically, for each animal 100 adipocytes from different hematoxylin-eosin-stained sections were analyzed by determining individual adipocyte areas (mM 2 ) using an image analyzer (Image Pro Plus, Milan, Italy). The data were pooled to represent a mean value and a statistical analysis was applied to compare the results obtained from the different experimental groups with a statistical significance set at Po0.05. The data were presented as the mean±s.d.
Western blot analysis of HO-1, adiponectin, gp phox91 and adipogenic markers Frozen adipose tissue was pulverized under liquid nitrogen and placed in a homogenization buffer comprising (mmol l À 1 ): 10 phosphate buffer, 250 sucrose, 1 EDTA, 0.1 phenylmethanesulfonylfluoride, and 0.1% v/v tergitol, pH 7.5. Homogenates were centrifuged at 27 000 g for 10 min at 4 1C. The supernatant was isolated, and protein levels were assayed (Bradford Method). The supernatant was used for the determination of HO-1, gp phox91, adiponectin, Pref-1, fatty acid synthase, Wnt10b, Wnt5b, b-catenin, mest and CEBPa. Immunoblotting was performed in visceral adipose tissue as previously described.
19,21 b-Actin was used to ensure adequate sample loading for all western blots.
Cytokines, adiponectin, Ang II, renin and lipid profile measurements
The plasma levels of interleukin (IL)-6, monocyte chemotactic protein-1 (MCP-1) and the high molecular weight (HMW) form of adiponectin were determined using an enzyme-linked immunosorbent assay (ELISA) as previously described. 4, 21 Angiotensin II and renin was measured in plasma and visceral adipose tissues using an ELISA assay (Assay Gate, Inc., Ijamsville, MD, USA). Triglycerides and total low-density PPARd binding to HO-1 attenuates adipocyte dysfunction K Sodhi et al lipoprotein levels are measured in plasma using an ELISA assay (Assay Gate, Inc.).
Quantitative real-time PCR analysis
Total RNA was extracted from liver tissues using 5-Prime PerfectPure RNA Tissue Kit (Fisher Scientific Company, LLC, Waltham, MA, USA). Total RNA was read on a NanoDrop 2000 Spectrophotometer (Thermo Scientific, Wilmington, DE, USA) and cDNA was synthesized using iScript cDNA Synthesis kit (Bio-Rad, Hercules, CA, USA). PCR amplification of the cDNA was performed by quantitative real-time PCR using qPCR Core kit for SYBR Green I (Applied Biosystems, Grand Island, NY, USA). The thermocycling protocol consisted of 10 min at 95 1C, 40 cycles of 15 s at 95 1C, 30 s at 60 1C and finished with a melting curve ranging from 60 to 95 1C to allow distinction of specific products. Primers were designed specific to each gene using Primer Express 3.0 software (Applied Biosystems). Normalization was performed in separate reactions with primers to 18S mRNA (5 0 -TTCGAACGTCTGCCCTATCAA-3 0 and 5 0 -ATGGTAGGCACGGCGACTA-3 0 ).
Statistical analysis
Data are expressed as means ± s.e.m. Significance of difference in mean values was determined using one-way analysis of variance followed by the Newman-Keul's post hoc test. Po0.05 was considered to be significant.
RESULTS
Effect of the PPARd agonist on adipogenesis in mouse preadipocytes
To study the effects of Ang II on adipogenesis, in vitro, 3T3L1 cells were exposed to Ang II in a dose-dependent manner. At 10 mM, Ang II increased adipogenesis in mouse preadipocytes, measured as the relative absorbance of Oil Red O on day 7 of the experiment (Figure 1a ; Po0.05); follow-up in vitro experiments were performed with 10 mM of Ang II. We then studied the effects of the PPARd agonist on adipogenesis in mouse preadipocytes, in the absence or in the presence of Ang II (Figure 1b) . Our results show that concurrent administration of PPARd agonist significantly (Po0.05) decreased adipogenesis in preadipocytes treated with Ang II; this effect was not seen in experiments conducted with SnMP, the HO inhibitor (Figure 1b ; Po0.05).
Effect of the PPARd agonist on body weight and the metabolic profile As shown in Table 1 , animals with clipped kidneys have body weight similar to sham-operated animals. Liver weight, plasma glucose, serum triglycerides and total low-density lipoprotein levels were also not dissimilar between the two groups. Treatment Figure 1 . (a) Effect of increasing Ang II concentrations on adipogenesis in mouse preadipocytes. Lipid droplet area was measured as the relative absorbance of Oil Red O at day 7 after inducing adipogenesis as described in Materials and Methods (mean±s.e., *Po0.05 vs vehicle; n ¼ 6). (b) Effect of the PPARd-agonist (GW501516) and Ang II on adipogenesis in mouse preadipocytes. Adipogenesis was measured as the relative absorbance of Oil Red O at day 7 after inducing adipogenesis as described in Methods and procedures (mean±s.e., *Po0.05 vs vehicle; n ¼ 6).
with the PPARd agonist, alone or in combination with SnMP, did not affect these anthropometric and general metabolic parameters in Goldblatt's hypertensive rats.
Effect of the PPARd agonist on plasma renin and Ang II levels Quantitative analysis, performed on the plasma from Goldblatt's 2K1C and sham-operated animals, showed significant elevation of plasma renin (Po0.05) and Ang II levels in rats with a clipped kidney (Figures 2a and b) (Figure 3a ; Po0.05). Treatment with the PPARd agonist decreased renin levels (Po0.05) and this effect was reversed by administration of PPARd agonist and SnMP. Similarly, Ang II levels in visceral adipose tissue were increased in 2K1C1 rats as compared with control animals (Po0.05). The PPARd agonist decreased Ang II levels, and this effect was reversed by the concurrent administration of SnMP (Figure 3b ). Oxidative stress was assessed in visceral adipose tissues by the measurement of gp phox 91 protein expression level, which was increased in 2K1C rats when compared with control animals (Figure 3c ; Po0.05). PPARd agonist decreased the expression of gp phox 91 (Po0.05) while SnMP prevented this decrease (Po0.05). 
of the visceral adipose tissues revealed that cross-sectional area of the adipocytes from 2K1C rats was significantly higher when compared with control rats (Figure 4a; Po0.05). The adipocyte area is reduced in rats treated with the PPARd agonist and SnMP reverses this effect, indicating the interactive role of PPARd-HO-1 in regulating adipocyte hypertrophy and lipid accumulation (Po0.05). Apart from affecting size, adipocyte number was also modulated in 2K1C rats, showing a reduction, when compared with the control animals (Figure 4b ; Po0.05). The number of adipocytes increased in rats treated with the PPARd agonist, and treatment with SnMP decreased this adipocyte number (Po0.05). Though the body weight of rats did not change among the different groups (Table 1) , visceral fat content was significantly higher in 2K1C rats when compared with the control animals (Figure 4c ; Po0.05). 2K1C rats treated with the PPARd agonist showed a significant reduction in visceral fat content and the concurrent administration of SnMP produced an increase in visceral fat mass (Figure 4c) .
We also examined the hepatic lipid-oxidation pathways to ascertain their role in bringing about adipose tissue changes in the 2K1C rats as compared with the sham-operated rats. Rats with a clipped kidney had levels of carnitine palmitoyltransferase 1A (CPT1a) and mitochondrial uncoupling protein 2 (UCP2) mRNA not dissimilar from the controls (CPT1a: sham-1.41 ± 0.07 vs 2K1C-1.18 ± 0.15; UCP2: sham-1.38 ± 0.08 vs 2K1C-1.13 ± 0.10). It is noteworthy, however that treatment with the PPARd agonist increased (Po0.05) gene expression of both CPT1a and UCP2 in the 2K1C rats (CPT1a: 2K1C þ GW-2.45 ± 0.06; UCP2: 2K1C-2.15 ± 0.08; Po0.05 vs 2K1C). SnMP blocked this stimulatory effect of the PPARd agonist (CPT1a: 2K1C þ GW þ SnMP-1.70±0.10; UCP2: 2K1C þ GW þ SnMP-1.67±0.11; Po0.05 vs 2K1C þ GW).
Effect of PPARd agonist on adipogenic markers and adiponectin expression in visceral adipose tissue Our next set of experiments examined possible mechanisms involved in RAS-dependent stimulation of visceral adiposity.
We first studied the levels of Wnt10b, b-catenin and adiponectin to see whether they could account for the decrease in fat content in adipose tissues of 2KIC rats treated with the PPARd agonist. Wnt10b and b-catenin levels decreased in 2K1C rats as compared with control animals ( Figures 5a and b respectively; Po0.01). Administration of the PPARd agonist increased the Wnt10b and b-catenin expression; SnMP blocked this effect (Po0.05). Activation of the Wnt-signalling cascade promotes a lower differentiation state of pre-adipocytes, 22 and this was tested in our study via preadipocyte factor 1 (pref1) expression analysis (Figure 5c ). Pref1 is an adipocyte marker, expressed abundantly in pre-adipocytes. Animals with a clipped kidney expressed lower levels of pref1 (Po0.05). Pref1 expression was rescued by the PPARd agonist (Po0.05), an effect blocked by SnMP (Po0.05). Additionally, western blot analysis of adiponectin levels showed a significant reduction (Po0.05) in 2K1C rats as compared with control animals ( Figure 5d) ; Po0.05. The concurrent administration of the PPARd agonist increased (Po0.05) adiponectin expression and SnMP decreased this effect. These data suggest that an increase in PPARd-HO-1 axis improves adipocyte function and reduces adiposity through upregulation of adipocyte-protective adiponectin and activation of Wnt10b and b-catenin pathway.
Effect of PPARd agonist on adipogenic markers in visceral adipose tissue Experiments studying positive regulators of lipid accumulation and adipogenesis were examined next. Our results showed that positive regulators of adipogenesis mest, C/EBPa and Wnt5b levels were all increased significantly in 2K1C rats as compared with control animals (Figures 6a-c, respectively ; Po0.05). The concurrent administration of the PPARd agonist decreased mest, C/EBPa and Wnt5b expression, and this effect was increased by SnMP treatment in 2K1C animals (Po0.05). Additionally, fatty acid synthase expression (Figure 6d ; Po0.05) was elevated in rats with a clipped kidney. PPARd agonist treatment blocked this increase (Po0.05), which was restored when animals were co-treated with SnMP (Po0.05).
Effect of PPARd agonist on HO-1 levels in visceral adipose tissue We evaluated the proposed interplay between PPARd and HO systems in the 2K1C animal model. Western blot analysis showed a significant increase in HO-1 expression (Po0.05) in the visceral adipose tissue of 2K1C rats treated with the PPARd agonist, as compared with the 2K1C rats without treatment (Figure 7a) . Furthermore, our results showed that the concurrent administration of SnMP also increased HO-1 expression. These findings confirm our previous results with SnMP, which induced a significant increase in HO-1 expression but is a potent inhibitor of HO activity. 9 This effect of SnMP prevents heme degradation and inhibits formation of HO products, that is, CO and biliverdin.
To study the potential mechanistic link between PPARd and HO-1, we transiently transfected the HO-1 promoter luciferase construct into Cos 7 cells. Overexpression of PPARd cDNA and treatment with its agonist GW501516 significantly increased HO-1 promoter activity (Figure 7b ; Po0.05). In addition, our results show that there was no significant increase in HO-1 promoter activity in the absence of PPARd cDNA overexpression or with GW501516, suggesting that HO-1 is a PPARd-target gene.
DISCUSSION
Angiotensin II induces oxidative stress and contributes to various pathological conditions, including insulin resistance and the metabolic syndrome. 8, 23 In this regard, recent reports have indicated that inhibitors of the RAS attenuate oxidative stress and improve the metabolic profile in various animal models. 24 However, evidence linking Ang II with adipocyte size and function is scarce, thereby prompting the present study. Two complimentary lines of evidence highlight the first key finding of this study,that is, a stimulatory effect of Ang II on adipocyte size and lipid accumulation. First sets of experiments demonstrate a dose-dependent increase in lipogenesis: in rodent preadipocytes with exogenous Ang II. Complementary in vivo studies reveal that elevation of endogenous Ang II levels also lead to adipocyte hypertrophy and visceral adiposity. Redox imbalance has been shown to increase adipogenesis 5 that is characterized by adipocyte hypertrophy and dysfunction. 5 Goldblatt's 2K1clip animals are an established model of reno-vascular hypertension where upregulated RAS precipitates redox imbalance and oxidative stress. 9 These animals exhibit high blood pressure with increased plasma levels of renin and Ang II, including in adipose tissues. Increased visceral adiposity was evident in these animals in spite of less than significant change in their body and liver weight, blood glucose, serum triglycerides and low-density lipoprotein levels. This suggests that Ang II is directly responsible for the adipocyte hypertrophy that appears to be defined by its ability to modulate redox balance. Relevant to these findings, Ang II-induced increase in adiposity was characterized by depleted proliferation and enhanced lipid accumulation by visceral adipocytes: morphological characteristics frequently accompanied by adipocyte dysfunction. Increased circulating levels of inflammatory cytokines, and reduced adiponectin levels, both in the plasma and in the adipose tissues, substantiate Ang II-induced dysfunctional adipogenesis in the 2K1clip rats. Adiponectin is a cytoprotective adipokine used as a marker of adipocyte function. 3 Attenuation of adiponectin levels is frequently associated with enlarged, hypoxic adipocytes, which also demonstrate increased inflammatory infiltration. 25 These morpho-physiological alterations of the adipocytes are the hallmarks of obesity and metabolic syndrome. 22, 26 Association of these functional perturbations of adipocytes with elevated levels of Ang II implicates its role in bringing about these dysfunctions.
Redox-dependent modulation of Wnt10b/b-catenin (the canonical pathway) is an effect that underlies increased lipid accumulation and hypertrophic adipogenesis; this is commonly observed in clinico-pathological scenarios associated with oxidative stress. 22, 25 Wnt10b is an endogenous regulator of adipogenesis that functions as a 'switch' that retards adipocyte differentiation and maturation into lipid-laden cells. Activation of Wnt10b contributes to the inactivation/phosphorylation of glycogen synthase kinase-3b and, consequently, elevated level of b-catenin ( Figure 8) ; it is the molecular node of the canonical Wnt signaling pathway. 27 Conversely, Wnt5b, another component of the Wnt family, stimulates adipogenesis by inhibiting the b-catenin and the Wnt-signaling cascade. 28 Consistent with these findings, we found that the Wnt10b and b-catenin protein expression were downregulated and that the Wnt5b protein levels were increased in 2K1clip rats. Wnt10b maintains adipocytes in a reduced state of differentiation 22 as evident in our study by the expression of pref1. Pref1 is employed as a marker for adipocyte differentiation; abundant in pre-adipocytes, while the expression declines progressively as they mature and accumulate lipid droplets. Rats with overexpression of the RAS demonstrated attenuation of the Wnt-signalling cascade along with lower levels of pref1 protein. These observations, in conjunction with the morphological characteristics of the visceral adipose tissues, implicate RAS-mediated promotion of adipocyte growth and differentiation in these animals. Supportive evidence in this direction shows that RAS-induced dysfunctional adipogenesis is accompanied by increased expression of adipogenic regulatorsmest and CCAAT/enhancer binding protein (C/EBPa). An increase in Wnt/b-catenin signaling inhibits C/EBPa and mest levels, which are expressed during adipogenesis and have a crucial role in the transcriptional regulation of adipocyte genes. 25 The redox-dependent increase in adipogenesis and adipocyte hypertrophy is attenuated by exogenous antioxidants. 22 In this Figure 8 . A schematic summary of our hypotheses and obtained results. Angiotensin II, via redox-dependent mechanisms, promotes adipocyte growth and lipid accumulation. This involves the suppression of the Wnt-canonical pathway and leads to dysfunctional hypertrophic adipogenesis-characterized by increased visceral adiposity, increased inflammation and decreased adiponectin levels. A synthetic PPARd-agonist binds to and activates the HO-1 promoter, with increased HO-1 expression as a consequence. Activation of this pathway stimulates the Wnt-canonical signaling cascade in adipose tissues, subjected to higher levels of Ang II and oxidative stress. Consequentially, preadipocyte maturation and lipid accumulation is retarded, leading to an increased number of smaller adipocytes with improved adipocytokine profile. Thus, PPARdagonist-mediated HO-1 activation prevents oxidative stress and associated dysfunctional adipogenesis in animals with an overactive renin-angiotensin system. regard, PPARd-a ligand-activated transcription factor-regulates inflammation, energy homeostasis and reduces oxidative stress. 29 The second key finding presented in this study shows that a synthetic PPARd agonist, GW501516, attenuates Ang II-mediated increase in adipogenesis. Although the biological roles of PPARa/PPARg in modulating metabolic homeostasis are well established, 30 contributions of PPARd to this process remain unclear. Our results show that the pro-adipogenic effects of AngII, both in vitro and in vivo, are prevented by treatment with a PPARd agonist, manifest by an improvement in adipocyte function and an abatement of the inflammatory response. A concomitant attenuation in adipose tissue oxidative stress and adiponectin rescue by GW501506 underscores the ability of PPARd activation to restore redox balance. This could, in turn, contribute towards the restoration of adipose tissue abnormalities observed in a setting of elevated levels of AngII. The patho-physiological recovery, in animals treated with a PPARd agonist, was accompanied by the rescue of the Wnt-canonical pathway that, in turn, retards adipocyte maturation into large lipid-laden cells. PPARd agonist-induced effects on adipocyte differentiation are embodied by the increased expression of pre-adipocyte markerpref1. In addition, the observed suppression of pro-adipogenic regulators, mest1 and C/EBPa, support the hypothesis that activation of PPARd via an exogenous synthetic agonist leads to the attenuation of lipid accumulation and adipocyte hypertrophy. These results are bolstered with reports characterizing increased lipolysis and reduced adiposity in transgenic animals treated with the PPARd agonist. 12 Although 2K1C animals have similar hepatic lipid oxidation as their sham-operated counterparts, PPARd agonist did induce these biochemical processes in the treated animals. This may be one of the contributing factors towards the agonist-induced attenuation of adiposity, in the in vivo setting. These results are unsurprising, as the PPARs have been shown to modulate lipid-oxidation pathways in models of diet-induced obesity. 12, 31 What was unexpected was the failure of this agonist to affect the metabolic profile of the animals in our study. Despite reducing visceral adiposity and inflammation, the PPARd agonist had no effect on the metabolic profile of the treated animals. These observations, while unexplained by the study, lend themselves to a few hypotheses: firstly, enhanced adiposity in these animals was not initiated by dietary alterations, rather by induction of tissue oxidative stress; it is also possible that a more chronic study with or without additional dietary modifications may allow a better understanding of the patho-physiological mechanisms involved in the redox-initiated adipogenic processes.
The heme-HO system has therapeutic potential in clinicopathological conditions frequently associated with chronic oxidative stress. 17, 19 That AngII-dependent cardio-vascular pathologies in the 2k1clip model of hypertension are rescued in animals with increased levels of HO1 is evidence of the ability of this antioxidant system to reverse the ROS-dependent effects of AngII. 9, 17, 32 In light of this evidence, we examined the role of transcriptional stimulation of HO1 by the PPARd agonist, and its role in restoring adipocyte structure and function in models with elevated AngII. The third key finding of this study shows that the PPARd agonist-mediated rescue of effects of AngII on adipose tissues is reliant upon activation of the heme-HO system. Multiple lines of evidence support this conclusion: firstly, attenuation of visceral adiposity and improvement in adipocyte function, observed in animals with clipped kidney and treated with GW501516, was paralleled by upregulation of HO1. Secondly, morpho-physiological rescue of the adipose tissues by the PPARd agonist, both in vitro and in vivo, was prevented in a setting where HO activity is blocked. And finally, stimulation of HO1 promoter by the PPARd-agonist implicates PPARd binding to the HO promoter. Further supporting evidence to the involvement of the heme-HO system is provided by recovery of the Wnt-canonical pathway in animals treated with the PPARd agonist. Previous reports have shown the stimulatory effects of heme-HO on Wnt10b signaling, 22 and we have evidence linking this effect of HO-1 to its anti-adipogenic properties (unpublished work).
To conclude as represented in the schematic (Figure 8 ), we show here that AngII has a stimulatory effect on adipogenesis and adipocyte lipid accumulation, with a concomitant decline in adipocyte function, as evidenced by the downregulation of the protective adipokine-adiponectin. These effects of AngII contribute towards enhanced visceral adiposity in an animal model displaying elevation of the RAS. Suppression of the Wnt-canonical-signaling pathways with a concomitant increase in the pro-adipogenic regulators, such as mest, C/EVBPa and the fatty acid synthase, appear to underlie the effects of Ang II. An exogenous PPARd agonist suppresses the AngII-induced dysfunctional adipogenesis and lipid accumulation, while stimulating the Wnt-canonical pathway. Also contributing to this effect is the upregulation of the hepatic lipid-oxidation processes by the PPARd agonist. These actions of the PPARd agonist are, in turn, reliant upon the transcriptional activation of the heme-HO system. Antiredox properties of the HO system underlie, at least partly, the therapeutic benefits obtained from GW501506.
